MedTrace Logo

Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients

NCT05065658 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249

Last updated 2025-02-17

Study results available
· View outcomes & findings →

Summary

COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients. This study will investigate the efficacy of mold-active prophylaxis with posaconazole for patients with severe SARS (severe acute respiratory syndrome)-CoV-2 infection admitted to the ICU (intensive care unit) in a multi-center case-control study in Europe.

Conditions

  • COVID-19 Respiratory Infection
  • Aspergillosis

Interventions

DRUG

Posaconazole

Intravenous posaconazole prophylaxis

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2023-08-23
Completion
2023-08-23

Countries

  • Austria
  • France
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065658 on ClinicalTrials.gov